RESEARCH PAPER
Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer
 
More details
Hide details
1
2nd Department of Obstetrics and Gynecology, Medical University, Warsaw, Poland
2
Department of Obstetrics and Gynecology Didactics, Medical University, Warsaw, Poland
3
Department of Pathology, The Medical Center of Postgraduate Education, Warsaw, Poland
4
Department of Gynecological Endocrinology, Medical University, Warsaw, Poland
5
Department of Immunology, Cenrtre for Biostructure Research, Medical University, Warsaw, Poland
6
Laboratory of Experimental Medicine, Centre of New Technologies, Warsaw University, Poland
CORRESPONDING AUTHOR
Jacek Sieńko   

2nd Department of Obstetrics and Gynecology, Medical University of Warsaw, Karowa 2, 00-315, Warsaw, Poland
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Peroxiredoxin-1 (PRDX-1) belongs to a family of antioxidant enzymes and has proved to be a versatile molecule regulating cell growth, differentiation and apoptosis. PRDX1-regulated signaling pathways play an important role in the progression and metastasis of human tumours, especially in breast, esophageal and lung cancers. The aim of the study was to evaluate the expression of PRDX-1 in ovarian cancer tissues, and to test the clinical value of PRDX-1 as a prognostic factor in this malignancy.

Material and methods:
PRDX-1 expression was assessed by automated immunohistochemistry in tumours taken from 55 patients with ovarian cancer during primary surgery. Specimen were formalin-fixed and preserved in paraffin-embedded blocks. The results were correlated with clinicopathological data.

Results:
A high expression of PRDX-1 was observed in 20% of cases, and was associated with worse compliance to chemotherapy protocol (P<0.002), worse response to chemotherapy (P<0.04), and higher levels of CA 125 after the 1st line treatment (P<0.004). PRDX-1 positive subjects had a significantly lower 5-year disease-free survival (9.1% vs. 42.6%, P<0.01) and a lower 5-year overall survival (9.1% vs. 56.7%; P<0.002). Multivariate analysis showed that a high expression of PRDX-1 is an independent prognostic factor of poor, overall survival (P<0.002) and a disease-free survival (P<0.01).

Conclusions:
Results of the study show that PRDX-1 expression in tumour tissues can be another biomarker of prognosis in patients with ovarian cancer.

ACKNOWLEDGEMENTS
The work was supported by the Ministry of Science and Higher Education grant (IP2012048172; DN)
 
REFERENCES (34)
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018; 68(1): 7–30.
 
2.
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics. CA Cancer J Clin. 2018; 68: 284–296.
 
3.
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; 10 (8): CD007565.
 
4.
Kebapci E, Gülseren V, Tugmen C, Gökçü M, Solmaz U, Sert J, et al. Outcomes of patients with advanced stage ovarian cancer with intestinal metastasis. Ginekol Pol. 2017; 88(10): 537–542.
 
5.
Oseledchyk A, Hunold LE, Mallmann MR, Domröse CM, Abramian A, Debald M, et al. Impact of Extended Primary Surgery on Suboptimally Operable Patients with Advanced Ovarian Cancer. Int J Gynecol Cancer. 2016; 26(5): 873–83.
 
6.
Pinato DJ, Graham J, Gabra H, Sharma R. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev. 2013; 39(2): 153–60.
 
7.
Koo YJ, Lim KT. Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients. Taiwan J Obstet Gynecol. 2015; 54(3): 275–9.
 
8.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15(8): 852–61.
 
9.
Wood ZA, Schroder E, Robin HJ, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2013; 28 (1): 32–40.
 
10.
Ding C, Fan X, Wu G. Peroxiredoxin 1 – an antioxidant enzyme in cancer. J Cell Mol Med. 2017; 21(1): 193–202.
 
11.
Kim JH, Lee JM, Lee HN, Kim EK, Ha B, Ahn SM, et al. RNA-binding properties and RNA chaperone activity of human peroxiredoxin 1. Biochem Biophys Res Commun. 2012; 425 (4): 730–734.
 
12.
Rhee SG, Woo HA. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H2O2, and protein chaperones”. Antioxid Redox Signal. 2011; 15: 781–94.
 
13.
Hopkins BL, Neumann CA. Redoxins as gatekeepers of the transcriptional oxidative stress response. Redox Biol. 2019; 21: 101104.
 
14.
Graves JA, Metukuri M, Scott D, et al. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. J Biol Chem. 2009; 284(10): 6520–9.
 
15.
Zhang M, Hou M, Ge L, Miao C, Zhang J, Jing X, Shi N, Chen T, Tang X. Induction of peroxiredoxin 1 by hypoxia regulates heme oxygenase-1 via NF-κB in oral cancer. PLoS One. 2014; 9(8): e105994.
 
16.
Chhipa RR, Lee KS, Onate S, et al. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res. 2009; 7: 1543–52.
 
17.
Rostila A, Puustinen A, Toljamo T, Vuopala K, Lindström I, Nyman TA, et al. Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure. Lung Cancer. 2012; 77(2): 450–9.
 
18.
Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res. 2009; 28: 93.
 
19.
Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through toll-like receptor 4-dependent regulation of tumour vasculature. Cancer Res. 2011; 71(5): 1637–1646.
 
20.
Ren P, Ye H, Dai L, Liu M, Liu X, Chai Y, et al. Peroxiredoxin 1 is a tumour-associated antigen in esophageal squamous cell carcinoma. Oncol Rep. 2013; 30: 2297–303.
 
21.
Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, et al. Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. 2014; 31(1): 786.
 
22.
Byun JM, Kim SS, Kim KT, Kang MS, Jeong DH, Lee DS, et al. Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer. Oncol Lett. 2018; 15(4): 5111–5118.
 
23.
Wang X, He S, Sun JM, et al. Selective association of peroxiredoxin 1 with genomic DNA and COX?2 upstream promoter elements in estrogen receptor negative breast cancer cells. Mol Biol Cell. 2010; 21: 2987–95.
 
24.
Woolston CM, Storr SJ, Ellis IO, Morgan DA, Martin SG. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer”. Radiother Oncol. 2011; 100: 308–13.
 
25.
O’Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, et al. Peroxiredoxin 1 protects estrogen receptor from oxidative stress induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Res. 2014; 16: R79.
 
26.
Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, et al. Histone deacetylase inhibitor FK228 activates tumour suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res. 2005; 11: 7945–52.
 
27.
Sienko J, Gaj P, Czajkowski K, Nowis D. Peroxiredoxin-5 is a negative survival predictor in ovarian cancer. Gin Pol. 2019; 90(1): 1–6.
 
28.
Cai CY, Zhai LL, Wu Y, Tang ZG. Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer. Eur J Surg Oncol. 2015; 41(2): 228–35.
 
29.
Kalinina EV, Berezov TT, Shtil’ AA, Chernov NN, Glazunova VA, Novichkova MD, et al. Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med. 2012; 153(6): 878–81.
 
30.
Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma”. J Proteomics. 2013; 8(91): 393–404.
 
31.
Li S, Hu X, Ye M, Zhu X. The prognostic values of the peroxiredoxins family in ovarian cancer. Biosci Rep. 2018; 38(5).
 
32.
Du ZX, Yan Y, Zhang HY, et al. Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells. Endocr Relat Cancer. 2010; 17: 553–60.
 
33.
Gong F, Hou G, Liu H, et al. Peroxiredoxin 1 promotes tumourigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. Med Oncol. 2015; 32: 455.
 
34.
Peroja P, Haapasaari KM, Mannisto S, Miinalainen I, Koivunen P, Leppä S, et al. Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma. Virchows Arch. 2016; 468(5): 623–30.
 
eISSN:1898-2263
ISSN:1232-1966